Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While stem cell transplants can cure the condition, their use is limited due to some of the risks that come with them. Also known as lovo-cel, bluebird bio’s product is a lentiviral gene therapy.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

Drug Discovery World

OCTOBER 31, 2023

The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of Manchester in August 2022.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

XTalks

DECEMBER 13, 2023

While Lyfgenia delivers a functional copy of hemoglobin A to replace the abnormal one in hematopoietic (blood) stem cells via a lentiviral vector, Casgevy edits the HBB gene using CRISPR technology to increase the production of fetal hemoglobin in blood stem cells. Both therapies will be available in early 2024.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Delveinsight

FEBRUARY 25, 2021

Working with Quest will help them support convenient access to blood collection for patients and healthcare providers. A new study from UCLA and Stanford University researchers observes that three-dimensional human stem cell-derived brain organoids can mature in a strikingly similar way to human brain development.

DNA 52

DNA In-Vivo Genetics Medicine 52

pharmaphorum

DECEMBER 2, 2020

“Pfizer is the 6th largest lobbier in Washington, and spent $25 million on lobbying during the passing of Obama’s healthcare reform legislation alone” Ups and downs. For all the latest Pfizer news follow pharmaphorum’s Pfizer tag. The post A history of Pfizer appeared first on.

Sales 128

Sales Production Drugs Marketing 128

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Immunocytokines Following chairperson’s remarks from Stefan Zielonka, PhD, Global Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA; Professor of Biomolecular Immunotherapy, Technical University of Darmstadt, there will be a keynote presentation from Roberto De Luca, PhD, Head, Therapeutic Antibodies, Philochem.

Protein 59

Protein Antibody Engineer Scientist 59